Carboplatin in Combination with Bendamustine in Previously Untreated Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-10

AUTHORS

Wolf Köster, G. Stamatis, A. Heider, K. Avramidis, H. Wilke, J.A. Koch, M. Stahl

ABSTRACT

Background and objective: Bendamustine is an alkylating agent with high efficacy in non-Hodgkin’s lymphoma and multiple myeloma. Even in solid tumours, monotherapy with bendamustine has resulted in subjective remissions and has been associated with a low rate of side effects. The current dose-finding study was designed to determine the maximum tolerated dose (MTD) of combined carboplatin/bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC).Patients and methods: Carboplatin was administered as a 1-hour infusion on day 1 at increasing dose levels, and bendamustine was administered as a short infusion on days 1 and 2 at increasing dose levels (80–120 mg/m2). The regimen was administered every 3 weeks. Four dose levels were planned, starting with 80 mg/m2 bendamustine and carboplatin area under the curve (AUC) 5 (dose level I). The other dose levels were 100 mg/m2 bendamustine and carboplatin AUC 5 (dose level II), 100 mg/m2 bendamustine and carboplatin AUC 6 (dose level III), and 120 mg/m2 bendamustine and carboplatin AUC 6 (dose level IV). A minimum of three patients were enrolled at each dose level.Results: Dose-limiting toxicities, which included fatigue, infection and tachyarrhythmia, were observed at dose level III. The recommended dose for phase II studies was therefore established at dose level II. The majority of haematological and non-haematological toxicities observed were only mild (grade 1 or 2) in patients at dose levels I and II. None of the patients developed severe alopecia. Objective responses were observed in eight of the ten patients involved in this trial.Conclusion: Because of its acceptable toxicity and favourable preliminary antitumour efficacy, the combination of carboplatin and bendamustine appears to be a potentially useful chemotherapeutic option in patients with extensive SCLC. More... »

PAGES

611-618

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00044011-200424100-00007

DOI

http://dx.doi.org/10.2165/00044011-200424100-00007

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052951906

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17523723


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.461714.1", 
          "name": [
            "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00f6ster", 
        "givenName": "Wolf", 
        "id": "sg:person.0742143752.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742143752.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ruhrlandklinik Essen, Essen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.477805.9", 
          "name": [
            "Ruhrlandklinik Essen, Essen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stamatis", 
        "givenName": "G.", 
        "id": "sg:person.0743515207.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743515207.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinikum Leverkusen, Leverkusen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.419829.f", 
          "name": [
            "Klinikum Leverkusen, Leverkusen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heider", 
        "givenName": "A.", 
        "id": "sg:person.01056372352.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056372352.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.461714.1", 
          "name": [
            "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Avramidis", 
        "givenName": "K.", 
        "id": "sg:person.01124505552.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124505552.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.461714.1", 
          "name": [
            "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilke", 
        "givenName": "H.", 
        "id": "sg:person.011000603017.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011000603017.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.461714.1", 
          "name": [
            "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koch", 
        "givenName": "J.A.", 
        "id": "sg:person.01230075746.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230075746.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.461714.1", 
          "name": [
            "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stahl", 
        "givenName": "M.", 
        "id": "sg:person.0616031606.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616031606.75"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s007610050290", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048745128", 
          "https://doi.org/10.1007/s007610050290"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s004320050225", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045393304", 
          "https://doi.org/10.1007/s004320050225"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-10", 
    "datePublishedReg": "2004-10-01", 
    "description": "Background and objective: Bendamustine is an alkylating agent with high efficacy in non-Hodgkin\u2019s lymphoma and multiple myeloma. Even in solid tumours, monotherapy with bendamustine has resulted in subjective remissions and has been associated with a low rate of side effects. The current dose-finding study was designed to determine the maximum tolerated dose (MTD) of combined carboplatin/bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC).Patients and methods: Carboplatin was administered as a 1-hour infusion on day 1 at increasing dose levels, and bendamustine was administered as a short infusion on days 1 and 2 at increasing dose levels (80\u2013120 mg/m2). The regimen was administered every 3 weeks. Four dose levels were planned, starting with 80 mg/m2 bendamustine and carboplatin area under the curve (AUC) 5 (dose level I). The other dose levels were 100 mg/m2 bendamustine and carboplatin AUC 5 (dose level II), 100 mg/m2 bendamustine and carboplatin AUC 6 (dose level III), and 120 mg/m2 bendamustine and carboplatin AUC 6 (dose level IV). A minimum of three patients were enrolled at each dose level.Results: Dose-limiting toxicities, which included fatigue, infection and tachyarrhythmia, were observed at dose level III. The recommended dose for phase II studies was therefore established at dose level II. The majority of haematological and non-haematological toxicities observed were only mild (grade 1 or 2) in patients at dose levels I and II. None of the patients developed severe alopecia. Objective responses were observed in eight of the ten patients involved in this trial.Conclusion: Because of its acceptable toxicity and favourable preliminary antitumour efficacy, the combination of carboplatin and bendamustine appears to be a potentially useful chemotherapeutic option in patients with extensive SCLC.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00044011-200424100-00007", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "keywords": [
      "small cell lung cancer", 
      "extensive-stage small-cell lung cancer", 
      "cell lung cancer", 
      "m2 bendamustine", 
      "dose levels", 
      "AUC 6", 
      "untreated patients", 
      "lung cancer", 
      "day 1", 
      "extensive small cell lung cancer", 
      "dose level III", 
      "dose level II", 
      "non-haematological toxicity", 
      "phase II study", 
      "combination of carboplatin", 
      "dose level I", 
      "dose-finding study", 
      "subjective remission", 
      "AUC 5", 
      "carboplatin area", 
      "II study", 
      "objective response", 
      "acceptable toxicity", 
      "Hodgkin's lymphoma", 
      "multiple myeloma", 
      "short infusion", 
      "chemotherapeutic options", 
      "antitumour efficacy", 
      "severe alopecia", 
      "bendamustine", 
      "curve 5", 
      "side effects", 
      "Level I", 
      "patients", 
      "solid tumors", 
      "level III", 
      "level II", 
      "carboplatin", 
      "high efficacy", 
      "dose", 
      "lymphoma", 
      "infusion", 
      "lower rates", 
      "cancer", 
      "efficacy", 
      "toxicity", 
      "monotherapy", 
      "remission", 
      "regimen", 
      "tachyarrhythmias", 
      "levels", 
      "myeloma", 
      "alopecia", 
      "tumors", 
      "infection", 
      "trials", 
      "weeks", 
      "study", 
      "options", 
      "majority", 
      "agents", 
      "fatigue", 
      "response", 
      "combination", 
      "background", 
      "rate", 
      "effect", 
      "objective", 
      "area", 
      "method", 
      "minimum", 
      "maximum"
    ], 
    "name": "Carboplatin in Combination with Bendamustine in Previously Untreated Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)", 
    "pagination": "611-618", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052951906"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00044011-200424100-00007"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17523723"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00044011-200424100-00007", 
      "https://app.dimensions.ai/details/publication/pub.1052951906"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_391.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00044011-200424100-00007"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00044011-200424100-00007'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00044011-200424100-00007'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00044011-200424100-00007'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00044011-200424100-00007'


 

This table displays all metadata directly associated to this object as RDF triples.

190 TRIPLES      22 PREDICATES      101 URIs      91 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00044011-200424100-00007 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nca81e337d2f54ffc8c3d4b6e0ee2af06
4 schema:citation sg:pub.10.1007/s004320050225
5 sg:pub.10.1007/s007610050290
6 schema:datePublished 2004-10
7 schema:datePublishedReg 2004-10-01
8 schema:description Background and objective: Bendamustine is an alkylating agent with high efficacy in non-Hodgkin’s lymphoma and multiple myeloma. Even in solid tumours, monotherapy with bendamustine has resulted in subjective remissions and has been associated with a low rate of side effects. The current dose-finding study was designed to determine the maximum tolerated dose (MTD) of combined carboplatin/bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC).Patients and methods: Carboplatin was administered as a 1-hour infusion on day 1 at increasing dose levels, and bendamustine was administered as a short infusion on days 1 and 2 at increasing dose levels (80–120 mg/m2). The regimen was administered every 3 weeks. Four dose levels were planned, starting with 80 mg/m2 bendamustine and carboplatin area under the curve (AUC) 5 (dose level I). The other dose levels were 100 mg/m2 bendamustine and carboplatin AUC 5 (dose level II), 100 mg/m2 bendamustine and carboplatin AUC 6 (dose level III), and 120 mg/m2 bendamustine and carboplatin AUC 6 (dose level IV). A minimum of three patients were enrolled at each dose level.Results: Dose-limiting toxicities, which included fatigue, infection and tachyarrhythmia, were observed at dose level III. The recommended dose for phase II studies was therefore established at dose level II. The majority of haematological and non-haematological toxicities observed were only mild (grade 1 or 2) in patients at dose levels I and II. None of the patients developed severe alopecia. Objective responses were observed in eight of the ten patients involved in this trial.Conclusion: Because of its acceptable toxicity and favourable preliminary antitumour efficacy, the combination of carboplatin and bendamustine appears to be a potentially useful chemotherapeutic option in patients with extensive SCLC.
9 schema:genre article
10 schema:inLanguage en
11 schema:isAccessibleForFree false
12 schema:isPartOf N64695fa9831b4c4a8bf226a338b03503
13 Ndc473d21f38f4f9bb00948a7aaaa3607
14 sg:journal.1100199
15 schema:keywords AUC 5
16 AUC 6
17 Hodgkin's lymphoma
18 II study
19 Level I
20 acceptable toxicity
21 agents
22 alopecia
23 antitumour efficacy
24 area
25 background
26 bendamustine
27 cancer
28 carboplatin
29 carboplatin area
30 cell lung cancer
31 chemotherapeutic options
32 combination
33 combination of carboplatin
34 curve 5
35 day 1
36 dose
37 dose level I
38 dose level II
39 dose level III
40 dose levels
41 dose-finding study
42 effect
43 efficacy
44 extensive small cell lung cancer
45 extensive-stage small-cell lung cancer
46 fatigue
47 high efficacy
48 infection
49 infusion
50 level II
51 level III
52 levels
53 lower rates
54 lung cancer
55 lymphoma
56 m2 bendamustine
57 majority
58 maximum
59 method
60 minimum
61 monotherapy
62 multiple myeloma
63 myeloma
64 non-haematological toxicity
65 objective
66 objective response
67 options
68 patients
69 phase II study
70 rate
71 regimen
72 remission
73 response
74 severe alopecia
75 short infusion
76 side effects
77 small cell lung cancer
78 solid tumors
79 study
80 subjective remission
81 tachyarrhythmias
82 toxicity
83 trials
84 tumors
85 untreated patients
86 weeks
87 schema:name Carboplatin in Combination with Bendamustine in Previously Untreated Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
88 schema:pagination 611-618
89 schema:productId N275e468215aa4bde91be6578c71c2323
90 N3fb6b4f5ca3f4f5d8d3d767c5dfa17a0
91 N6bf098e11d8d420fb5abec8825016518
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052951906
93 https://doi.org/10.2165/00044011-200424100-00007
94 schema:sdDatePublished 2022-05-20T07:22
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher Na235b04104e349269500d9e2703748fd
97 schema:url https://doi.org/10.2165/00044011-200424100-00007
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N275e468215aa4bde91be6578c71c2323 schema:name dimensions_id
102 schema:value pub.1052951906
103 rdf:type schema:PropertyValue
104 N2c65f4ee938a4eccb6b7f7ebabc11f85 rdf:first sg:person.011000603017.19
105 rdf:rest Na5a87839db694cc1bb29febce2caef35
106 N397bbaa1bf284291ae1d43ca6c5fcaf9 rdf:first sg:person.0743515207.27
107 rdf:rest Nfd5480febbbd4820ab21cfe09af0e42d
108 N3fb6b4f5ca3f4f5d8d3d767c5dfa17a0 schema:name doi
109 schema:value 10.2165/00044011-200424100-00007
110 rdf:type schema:PropertyValue
111 N64695fa9831b4c4a8bf226a338b03503 schema:issueNumber 10
112 rdf:type schema:PublicationIssue
113 N67437200b25f4f2a842687f1588f87ca rdf:first sg:person.01124505552.23
114 rdf:rest N2c65f4ee938a4eccb6b7f7ebabc11f85
115 N6bf098e11d8d420fb5abec8825016518 schema:name pubmed_id
116 schema:value 17523723
117 rdf:type schema:PropertyValue
118 Na235b04104e349269500d9e2703748fd schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 Na5a87839db694cc1bb29febce2caef35 rdf:first sg:person.01230075746.29
121 rdf:rest Nd8cf8fd430a94287b464230763ef0cdc
122 Nca81e337d2f54ffc8c3d4b6e0ee2af06 rdf:first sg:person.0742143752.53
123 rdf:rest N397bbaa1bf284291ae1d43ca6c5fcaf9
124 Nd8cf8fd430a94287b464230763ef0cdc rdf:first sg:person.0616031606.75
125 rdf:rest rdf:nil
126 Ndc473d21f38f4f9bb00948a7aaaa3607 schema:volumeNumber 24
127 rdf:type schema:PublicationVolume
128 Nfd5480febbbd4820ab21cfe09af0e42d rdf:first sg:person.01056372352.21
129 rdf:rest N67437200b25f4f2a842687f1588f87ca
130 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
131 schema:name Medical and Health Sciences
132 rdf:type schema:DefinedTerm
133 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
134 schema:name Oncology and Carcinogenesis
135 rdf:type schema:DefinedTerm
136 sg:journal.1100199 schema:issn 1173-2563
137 1179-1918
138 schema:name Clinical Drug Investigation
139 schema:publisher Springer Nature
140 rdf:type schema:Periodical
141 sg:person.01056372352.21 schema:affiliation grid-institutes:grid.419829.f
142 schema:familyName Heider
143 schema:givenName A.
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056372352.21
145 rdf:type schema:Person
146 sg:person.011000603017.19 schema:affiliation grid-institutes:grid.461714.1
147 schema:familyName Wilke
148 schema:givenName H.
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011000603017.19
150 rdf:type schema:Person
151 sg:person.01124505552.23 schema:affiliation grid-institutes:grid.461714.1
152 schema:familyName Avramidis
153 schema:givenName K.
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124505552.23
155 rdf:type schema:Person
156 sg:person.01230075746.29 schema:affiliation grid-institutes:grid.461714.1
157 schema:familyName Koch
158 schema:givenName J.A.
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230075746.29
160 rdf:type schema:Person
161 sg:person.0616031606.75 schema:affiliation grid-institutes:grid.461714.1
162 schema:familyName Stahl
163 schema:givenName M.
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616031606.75
165 rdf:type schema:Person
166 sg:person.0742143752.53 schema:affiliation grid-institutes:grid.461714.1
167 schema:familyName Köster
168 schema:givenName Wolf
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742143752.53
170 rdf:type schema:Person
171 sg:person.0743515207.27 schema:affiliation grid-institutes:grid.477805.9
172 schema:familyName Stamatis
173 schema:givenName G.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743515207.27
175 rdf:type schema:Person
176 sg:pub.10.1007/s004320050225 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045393304
177 https://doi.org/10.1007/s004320050225
178 rdf:type schema:CreativeWork
179 sg:pub.10.1007/s007610050290 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048745128
180 https://doi.org/10.1007/s007610050290
181 rdf:type schema:CreativeWork
182 grid-institutes:grid.419829.f schema:alternateName Klinikum Leverkusen, Leverkusen, Germany
183 schema:name Klinikum Leverkusen, Leverkusen, Germany
184 rdf:type schema:Organization
185 grid-institutes:grid.461714.1 schema:alternateName Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik für Innere Medizin I und IV, Internistische Onkologie/Hämatologie, Zentrum für Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany
186 schema:name Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik für Innere Medizin I und IV, Internistische Onkologie/Hämatologie, Zentrum für Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany
187 rdf:type schema:Organization
188 grid-institutes:grid.477805.9 schema:alternateName Ruhrlandklinik Essen, Essen, Germany
189 schema:name Ruhrlandklinik Essen, Essen, Germany
190 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...